Rafferty Asset Management LLC raised its position in shares of Allergan PLC. (NYSE:AGN) by 134.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,417 shares of the company’s stock after buying an additional 3,109 shares during the period. Rafferty Asset Management LLC’s holdings in Allergan PLC. were worth $1,294,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Baupost Group LLC MA increased its stake in shares of Allergan PLC. by 71.5% in the fourth quarter. Baupost Group LLC MA now owns 3,432,603 shares of the company’s stock worth $720,881,000 after buying an additional 1,430,625 shares in the last quarter. Trust Co. of Vermont increased its position in shares of Allergan PLC. by 62.8% in the first quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after buying an additional 1,109 shares during the last quarter. BKD Wealth Advisors LLC acquired a new position in shares of Allergan PLC. during the first quarter valued at about $219,000. Fulton Bank N.A. increased its position in shares of Allergan PLC. by 12.8% in the first quarter. Fulton Bank N.A. now owns 5,602 shares of the company’s stock valued at $1,338,000 after buying an additional 637 shares during the last quarter. Finally, Rehmann Capital Advisory Group increased its position in shares of Allergan PLC. by 15.4% in the first quarter. Rehmann Capital Advisory Group now owns 1,780 shares of the company’s stock valued at $425,000 after buying an additional 237 shares during the last quarter. 84.77% of the stock is currently owned by hedge funds and other institutional investors.

Allergan PLC. (AGN) traded down 0.61% during mid-day trading on Tuesday, reaching $239.74. 2,730,642 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $246.48 and a 200-day moving average price of $237.35. The stock has a market capitalization of $80.52 billion, a PE ratio of 7.47 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the previous year, the firm earned $3.35 EPS. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. Equities research analysts expect that Allergan PLC. will post $16.21 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.17%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/08/08/rafferty-asset-management-llc-purchases-3109-shares-of-allergan-plc-nyseagn-updated-updated-updated.html.

A number of equities research analysts recently commented on the company. Mizuho reiterated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company boosted their price target on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price on the stock in a research report on Monday, June 26th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $274.14.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.